Orexo Past Earnings Performance
Past criteria checks 0/6
Orexo's earnings have been declining at an average annual rate of -48.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 4.1% per year.
Key information
-48.3%
Earnings growth rate
-48.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | -4.1% |
| Return on equity | -50.8% |
| Net Margin | -24.8% |
| Next Earnings Update | 26 Jan 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Orexo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 612 | -152 | 390 | 310 |
| 30 Jun 22 | 597 | -177 | 408 | 297 |
| 31 Mar 22 | 592 | -216 | 409 | 289 |
| 31 Dec 21 | 565 | -223 | 432 | 272 |
| 30 Sep 21 | 580 | -207 | 374 | 251 |
| 30 Jun 21 | 585 | -240 | 409 | 238 |
| 31 Mar 21 | 621 | -198 | 408 | 228 |
| 31 Dec 20 | 664 | -84 | 389 | 225 |
| 30 Sep 20 | 743 | 4 | 368 | 225 |
| 30 Jun 20 | 824 | 201 | 322 | 216 |
| 31 Mar 20 | 846 | 288 | 341 | 197 |
| 31 Dec 19 | 845 | 219 | 332 | 181 |
| 30 Sep 19 | 834 | 232 | 413 | 170 |
| 30 Jun 19 | 819 | 182 | 421 | 166 |
| 31 Mar 19 | 818 | 178 | 364 | 159 |
| 31 Dec 18 | 783 | 138 | 358 | 167 |
| 30 Sep 18 | 747 | 113 | 275 | 156 |
| 30 Jun 18 | 697 | 79 | 268 | 147 |
| 31 Mar 18 | 656 | 32 | 274 | 149 |
| 31 Dec 17 | 644 | 23 | 287 | 134 |
| 30 Sep 17 | 637 | 19 | 230 | 133 |
| 30 Jun 17 | 653 | 27 | 256 | 128 |
| 31 Mar 17 | 682 | 29 | 303 | 118 |
| 31 Dec 16 | 706 | 29 | 324 | 132 |
| 30 Sep 16 | 752 | -57 | 419 | 154 |
| 30 Jun 16 | 710 | -139 | 434 | 173 |
| 31 Mar 16 | 648 | -229 | 430 | 183 |
| 31 Dec 15 | 646 | -210 | 439 | 173 |
Quality Earnings: ORXs is currently unprofitable.
Growing Profit Margin: ORXs is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORXs is unprofitable, and losses have increased over the past 5 years at a rate of 48.3% per year.
Accelerating Growth: Unable to compare ORXs's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORXs is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-41.9%).
Return on Equity
High ROE: ORXs has a negative Return on Equity (-50.84%), as it is currently unprofitable.